{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:25:51Z","timestamp":1793805951121,"version":"4.6.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA015083"],"award-info":[{"award-number":["P30 CA015083"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.urolonc.2026.06.010","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:34:20Z","timestamp":1783632860000},"page":"377-387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative effectiveness of intravesical gemcitabine vs. sequential gemcitabine and docetaxel for high-risk nonmuscle-invasive bladder cancer"],"prefix":"10.1016","volume":"44","author":[{"given":"Jacob A.","family":"Moyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnoor","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanyu","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Zganjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"Lyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paras H.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Boorjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5346-1404","authenticated-orcid":false,"suffix":"II","given":"Mark D.","family":"Tyson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.06.010_bib0001","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.puhe.2024.07.027","article-title":"Global, regional, and national burden of bladder cancer, 1990-2019: an age-period-cohort analysis based on the Global Burden of Disease 2019 study","volume":"236","author":"Zhang","year":"2024","journal-title":"Public Health"},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.010_bib0002","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.06.010_bib0003","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/JU.0000000000000593","article-title":"Use and validation of the AUA\/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort","volume":"203","author":"Ritch","year":"2020","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.010_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2019.05.018","article-title":"Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer","volume":"38","author":"Daniels","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.06.010_bib0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.urology.2023.02.044","article-title":"Variation in statewide intravesical treatment rates for non-muscle invasive bladder cancer during the Bacillus Calmette-Guerin drug shortage","volume":"177","author":"Chun","year":"2023","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.urolonc.2026.06.010_bib0006","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/14656566.2024.2310073","article-title":"Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?","volume":"25","author":"Chakra","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.urolonc.2026.06.010_bib0007","unstructured":"Packiam VT, Gabrielson AT, Kates M. Intravesical gemcitabine and docetaxel for nonmuscle-invasive bladder cancer. American Urological Association; 2022. https:\/\/auanews.net\/issues\/articles\/2022\/june-2022\/intravesical-gemcitabine-and-docetaxel-for-nonmuscle-invasive-bladder-cancer. Accessed 14 July, 2025."},{"key":"10.1016\/j.urolonc.2026.06.010_bib0008","series-title":"BCG-unresponsive nonmuscle invasive bladder cancer: developing drug and biological products for treatment (U.S. department of health and human services)","year":"2024"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.010_bib0009","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International bladder cancer group consensus statement on clinical trial design for patients with bacillus Calmette-Guerin-exposed high-risk non-muscle-invasive bladder cancer","volume":"82","author":"Roumiguie","year":"2022","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.010_bib0010","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","article-title":"SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guerin","volume":"190","author":"Skinner","year":"2013","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.06.010_bib0011","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-Institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.06.010_bib0012","unstructured":"Common terminology criteria for adverse events (CTCAE). U.S. Department of Health and Human Services. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-8\u00d711.pdf"},{"issue":"11","key":"10.1016\/j.urolonc.2026.06.010_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2023.06.018","article-title":"Sequential intravesical gemcitabine\/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy","volume":"41","author":"Yim","year":"2023","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.06.010_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2022.10.030","article-title":"Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer","volume":"41","author":"Chevuru","year":"2023","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.06.010_bib0015","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.euo.2024.12.005","article-title":"Oncologic outcomes of sequential intravesical gemcitabine and Docetaxel compared with Bacillus Calmette-Gu\u00e9rin in patients with Bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle invasive bladder cancer","volume":"8","author":"Taylor","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.06.010_bib0016","doi-asserted-by":"crossref","DOI":"10.1111\/bju.70182","article-title":"Impact of BCG failure patterns on efficacy of intravesical gemcitabine\/docetaxel in high-risk non-muscle-invasive bladder cancer","author":"Scilipoti","year":"2026","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.urolonc.2026.06.010_bib0017","first-page":"18","article-title":"Survey: new NMIBC treatments face slow uptake","volume":"53","author":"Saylor","year":"2025","journal-title":"Urol Times"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:29:50Z","timestamp":1793802590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926005685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1078143926005685"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.06.010","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness of intravesical gemcitabine vs. sequential gemcitabine and docetaxel for high-risk nonmuscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}